Response to the study: 'Syringe plunger contamination by hazardous drugs: A comparative study,' by Stephen T Smith and Mark C Szlaczky 1
To the Editor:
I am writing to express concern regarding a study-'Syringe plunger contamination by hazardous drugs: A comparative study,' published online in March 2014 in the Journal of Oncology Pharmacy Practice and in this issue 20:5. This letter outlines the statistical and scientific issues with the study and our plans to pursue a repeat of the study.
Given the science-based design of our syringes and extensive verification testing we conduct on our products, we were surprised at the authors' findings as we know it is not possible to contaminate the syringe plunger with normal use. BD 60-ml syringes incorporate a feature known as a retaining ring located on the internal barrel surface proximal to the barrel opening. The purpose of the retaining ring is to ensure, by design, that the plunger rod is not pulled out of the barrel during normal use and that the plunger rod ribs never touch the internal barrel surface of the syringe, thus preventing any transfer of drug contamination.
Despite knowing that contamination of our syringes is not possible (based upon the tested syringe design), we immediately sought to replicate the study protocol. No contamination of cyclophosphamide was indicated on any of the 12 samples. The discrepancy between our results and the study authors' results-and the fact that the study results are in direct conflict with published worldwide studies 2-5 and wipe study analysis data from current PhaSeal customers (data on file at BD) that has consistently proven that syringes used in conjunction with BD PhaSeal significantly reduces and/or eliminates surface contamination in healthcare facilities-suggests that the study execution included variables that were not mentioned in the study.
Some basic concerns with the study are outlined below and we believe these variables, methods, and assumptions in the discussion section should be challenged:
. Flawed statistical analysis and assumption: The authors claim in the results section that the contamination level in BD syringes can be assumed to be normally distributed with an average of 1622 ng and a variance of 331 ng. If that were true, simple statistics would say that the chance of one of the 12 samples having no contamination (as indicated for syringe number 12) would be less than 1 in 10 million. . Lack of controls: The design of the study does not contain any type of controls with the exception of the two wipe samples done on the surface of the biological safety cabinet. There were no positive or negative controls, or positive recovery controls performed on either of the products to ensure there were no laboratory errors in analysis of the samples. . Differing sample sizes: The sample size in this study was small, as noted by the authors. Furthermore, equal number of sample sizes of both devices were not reported (n¼ 11 Equashield; n¼ 12 BD). There is no explanation as to the missing syringe results and/ or the reason that an equal sample size was not performed on both products in the study.
In conclusion, this study conflicts with the abundance of scientific studies that show significant reduction of hazardous drug surface contamination and human uptake when using BD PhaSeal with a standard syringe and is at odds with syringe design features. As a result, we will be pursuing an independent third party to repeat the study.
